Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The European Multiple System Atrophy-Study Group (EMSA-SG).

F Geser1, K Seppi, M Stampfer-Kountchev

  • 1Clinical Department of Neurology, Innsbruck Medical University, Austria.

Journal of Neural Transmission (Vienna, Austria : 1996)
|July 29, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and Behavior.

bioRxiv : the preprint server for biology·2026
Same author

Corrigendum to "Quick MSA-QoL: A validated, abbreviated health-related quality of life questionnaire for use in Multiple System Atrophy" [Park. Relat. Disord. (2024) 128 107143. doi: 10.1016/j.parkreldis.2024.107143].

Parkinsonism & related disorders·2025
Same author

Oral health care pathways for patients with epidermolysis bullosa: A position statement from the European reference network for rare skin diseases.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Quick MSA-QoL: A validated, abbreviated health-related quality of life questionnaire for use in Multiple System Atrophy.

Parkinsonism & related disorders·2024
Same author

Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment.

Journal of endocrinological investigation·2024
Same author

Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease.

Parkinsonism & related disorders·2023
This summary is machine-generated.

The European Multiple System Atrophy-Study Group (EMSA-SG) provides the first prospective data on multiple system atrophy (MSA) progression. This natural history study enables better planning for future neuroprotective clinical trials in MSA patients.

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Epidemiology

Background:

  • The European Multiple System Atrophy-Study Group (EMSA-SG) is an academic network established in 1999, comprising 23 centers across Europe and Israel.
  • The network focuses on multiple system atrophy (MSA), a rare neurodegenerative disorder.
  • Supported by the European Union, EMSA-SG aims to advance MSA research through collaborative efforts.

Purpose of the Study:

  • To establish a central Registry for European multiple system atrophy (MSA) patients.
  • To create a decentralized DNA Bank for genetic research.
  • To develop and validate the Unified MSA Rating Scale (UMSARS).
  • To conduct a Natural History Study (NHS) to understand disease progression.
  • To plan and implement interventional therapeutic trials for MSA.

Related Experiment Videos

Main Methods:

  • A computerized Registry collects diagnostic and therapeutic data from MSA patients.
  • A DNA Bank stores blood samples from patients and controls.
  • The Unified MSA Rating Scale (UMSARS) was developed and validated.
  • The Natural History Study (NHS) involves comprehensive assessments using various scales (UMSARS, UPDRS, MMSE, EQ-5D, SF-36, BDI) and autonomic function tests, with 6-monthly follow-ups for 24 months.
  • Magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) are used to identify surrogate markers of disease progression.

Main Results:

  • 412 patients were recruited into the Registry; probable MSA-P was the most common diagnosis (49%).
  • 507 patients donated DNA for research.
  • 131 patients were recruited into the NHS.
  • A rapid deterioration in motor function (26.1% UMSARS II) and activities of daily living (16.8% UMSARS I) was observed.
  • Motor progression correlated with lower baseline scores in motor, global disability, akinesia, or cerebellar subscales.
  • No significant deterioration in mental function was noted during the follow-up period.

Conclusions:

  • This study provides the first prospective data on the natural history and progression of multiple system atrophy (MSA).
  • The collected data and identified surrogate markers are crucial for effectively planning future multi-center neuroprotective intervention trials.
  • Clinical trials on growth hormone and minocycline in MSA have been completed or are nearing completion, demonstrating the network's progress.